5-[4-[2-(5-Ethylpyridin-2-yl)ethoxy]benzyl]-2-iminothiazolidin-4-one (CAS: 105355-26-8) is a thiazolidine-2,4-dione derivative representing an advanced intermediate in glitazone antidiabetic drug synthesis. The compound features the complete pharmacophoric framework of thiazolidinedione drugs, with the 2-imino functionality serving as a handle for conversion to the active 2,4-dione form through hydrolysis or oxidation. Its ethylpyridyl ethoxy benzyl substituent provides the lipophilic character required for PPAR-gamma nuclear receptor activation, which enhances insulin sensitivity in target tissues. This intermediate is typically produced under stringent quality controls to ensure high chemical purity for pharmaceutical manufacturing. It represents a convergent stage in multi-step synthesis, enabling efficient completion of final API processing. Proper documentation and handling per pharmaceutical intermediate standards support its use in regulated drug production environments.
5-[4-[2-(5-Ethylpyridin-2-yl)ethoxy]benzyl]-2-iminothiazolidin-4-one
5-[4-[2-(5-Ethylpyridin-2-yl)ethoxy]benzyl]-2-iminothiazolidin-4-one (CAS: 105355-26-8) is a thiazolidine-2,4-dione derivative representing an advanced intermediate in glitazone antidiabetic drug synthesis. The compound features the complete pharmacophoric framework of thiazolidinedione drugs, with the 2-imino functionality serving as a handle for conversion to the active 2,4-dione form through hydrolysis or oxidation. Its ethylpyridyl ethoxy benzyl substituent provides the lipophilic character required for PPAR-gamma nuclear receptor activation, which enhances insulin sensitivity in target tissues. This intermediate is typically produced under stringent quality controls to ensure high chemical purity for pharmaceutical manufacturing. It represents a convergent stage in multi-step synthesis, enabling efficient completion of final API processing. Proper documentation and handling per pharmaceutical intermediate standards support its use in regulated drug production environments.
– Pioglitazone Intermediate: Used as an advanced precursor converting to pioglitazone API through final oxidation or hydrolysis steps.
– PPAR Agonist Synthesis: Serves as the pharmacophoric core for constructing thiazolidinedione insulin sensitizers.
– Process Chemistry: Applied in optimized synthetic routes reducing step count for glitazone manufacturing.
– Pharmaceutical Research: Employed in developing analogs with improved efficacy and reduced side effect profiles.
Product Name: 5-[4-[2-(5-Ethylpyridin-2-yl)ethoxy]benzyl]-2-iminothiazolidin-4-one
For global customers, we provide complete technical documentation to support product evaluation, regulatory compliance and safe handling during transportation and application.